介绍一种不影响D2受体的新型抗精神病候选药物：SEP-363856
Introducing a Novel Antipsychotic Candidate Drug That Does Not Affect D2 Receptors: SEP-363856
DOI: 10.12677/pi.2024.136056, PDF,   
作者: 周小东：中国人民解放军联勤保障部队第980医院(白求恩国际和平医院)精神心理科，河北 石家庄；中国融通集团医疗健康管理公司正定二五六医院精神卫生中心，河北 正定；刘知霞, 贾慧贤, 胡兴娟, 王 朋, 张俊纳：中国融通集团医疗健康管理公司正定二五六医院精神卫生中心，河北 正定；刘知源*：中国人民解放军联勤保障部队第983医院心理科，天津；张光勇*：四川省绵阳市第三人民医院精神卫生中心，四川 绵阳
关键词: 新型抗精神病药物(SEP-363856)；精神分裂症；疗效；安全性；耐受性；Novel Psychotropic Agent (SEP-363856)； Schizophrenia； Effect； Safety； Tolerance
摘要: 本文介绍一种在2020年被美国FDA批准用于临床精神分裂症的新型抗精神分裂症药物：SEP-363856。从该药物的药代动力学、受体作用机制、临床运用情况以及安全性和不良反应等方面作了总结。结论：SEP-363856治疗精神分裂症的阴、阳性症状均有效，且安全性、耐受性好，需要进一步扩大样本研究。
Abstract: The article introduces a novel antipsychotic drug, SEP-363856, approved by US FDA for clinical use in schizophrenia in 2020. A summary was made on the pharmacokinetics, receptor mechanism of action, clinical application, safety, and adverse reactions of the drug. Conclusion: SEP-363856 is effective in treating both negative and positive symptoms of schizophrenia and is safe and well tolerated. Further expansion of sample research is needed.
文章引用：周小东, 刘知霞, 贾慧贤, 胡兴娟, 王朋, 张俊纳, 刘知源, 张光勇. 介绍一种不影响D2受体的新型抗精神病候选药物：SEP-363856[J]. 药物资讯, 2024, 13(6): 475-481. https://doi.org/10.12677/pi.2024.136056

参考文献

[1] Koblan, K.S., Kent, J., Hopkins, S.C., Krystal, J.H., Cheng, H., Goldman, R., et al. (2020) A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. New England Journal of Medicine, 382, 1497-1506. [Google Scholar] [CrossRef] [PubMed]
[2] (2020) Sunovion and Psychogenics Announce That SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia.
https://www.businesswire.com
[3] Dedic, N., Jones, P.G., Hopkins, S.C., Lew, R., Shao, L., Campbell, J.E., et al. (2019) SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics, 371, 1-14. [Google Scholar] [CrossRef] [PubMed]
[4] Liu, H., Zheng, Y., Wang, Y., Wang, Y., He, X., Xu, P., et al. (2023) Recognition of Methamphetamine and Other Amines by Trace Amine Receptor TAAR1. Nature, 624, 663-671. [Google Scholar] [CrossRef] [PubMed]
[5] Christian, S.L. and Berry, M.D. (2018) Trace Amine-Associated Receptors as Novel Therapeutic Targets for Immunomodulatory Disorders. Frontiers in Pharmacology, 9, Article 680. [Google Scholar] [CrossRef] [PubMed]
[6] Koblan, K., Hopkins, S., Kent, J., et al. (2019) Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial. European Neuropsychopharmacology, 29, S85-S86. [Google Scholar] [CrossRef] 
[7] Dedic, N., Jones, P.G., Hopkins, S.C., Lew, R., Shao, L., Campbell, J.E., et al. (2019) SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics, 371, 1-14. [Google Scholar] [CrossRef] [PubMed]
[8] Miyamoto, S., Duncan, G.E., Marx, C.E. and Lieberman, J.A. (2004) Treatments for Schizophrenia: A Critical Review of Pharmacology and Mechanisms of Action of Antipsychotic Drugs. Molecular Psychiatry, 10, 79-104. [Google Scholar] [CrossRef] [PubMed]
[9] Karam, C.S., Ballon, J.S., Bivens, N.M., Freyberg, Z., Girgis, R.R., Lizardi-Ortiz, J.E., et al. (2010) Signaling Pathways in Schizophrenia: Emerging Targets and Therapeutic Strategies. Trends in Pharmacological Sciences, 31, 381-390. [Google Scholar] [CrossRef] [PubMed]
[10] Girgis, R.R., Zoghbi, A.W., Javitt, D.C. and Lieberman, J.A. (2019) The Past and Future of Novel, Non-Dopamine-2 Receptor Therapeutics for Schizophrenia: A Critical and Comprehensive Review. Journal of Psychiatric Research, 108, 57-83. [Google Scholar] [CrossRef] [PubMed]
[11] Milanovic, S., Origala, A., Dworak, H., Hopkins, S. and Koblan, K. (2020) M208. Measures of Cognition and Social Functioning in Schizophrenia Patients Receiving SEP-363856. Schizophrenia Bulletin, 46, S215-S216. [Google Scholar] [CrossRef] 
[12] Begni, V., Sanson, A., Grayson, B., Neill, J. and Riva, M.A. (2019) T109. Modulatory Activity of the Novel Drug Sep-363856 on Brain Function: Potential Application for the Treatment of Schizophrenia. Schizophrenia Bulletin, 45, S246-S246. [Google Scholar] [CrossRef] 
[13] Koblan, K., Hopkins, S., Justine, K., Hailong, C., Goldman, R. and Loebel, A. (2019) O12.5. Efficacy and Safety of Sep-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial. Schizophrenia Bulletin, 45, S199. [Google Scholar] [CrossRef]